Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Good afternoon and greetings from sunny Helsinki. Welcome to Orion's half-year financial report. January-June 2026 conference call and webcast. My name is Tuukka Hirvonen and I'm the Head of Investor Relations here at Orion. In a few moments, our CEO, Liisa Hurme, will go through the results and key events of the reported period, after which you will have the possibility to ask questions in the Q&A session to Liisa and also to CFO René Lindell. There is a possibility to ask questions through the conference call lines, but also by typing them in through the chat function in the webcast. We will start with the conference call lines and then turn to the webcast chat for our Finnish viewers. Please note that there will be a Finnish-speaking interview with CEO Liisa Hurme available on Orion's website later this afternoon. And just before letting Lisa take over. A brief reminder about the forward-looking statements in the presentation. And with these words, it is my pleasure to hand over to Lisa.
Thank you and good afternoon. On my behalf as well, we have once again delivered a strong quarter. Our net sales growth accelerated and also profitability improved during Q2. This was driven by Nubeqa royalties and product sales. And also our branded products division had an excellent quarter, and in research and development. We reached several key milestones, especially with ODM-212, and I will discuss that molecule later on in more detail. In Q2, our net sales increased by 25%, totaling €522 million, and operating profit increased by 69%, resulting in a 34% operating profit margin of €177 million, and earnings per share was €1.00. And of course, in our net sales development, Innovative Medicines was the main driver with €95 million. But also, when we look at Branded Products and the size of the Branded Products division, 10.3 million is a significant growth rate. All the other businesses were more or less on par. And on operating profit, the volume increased our profit by 17.3 million euros. The volume growth increased our profit by €17.3 million. Again, royalties played a key role here, contributing close to €77 million. We. We have also finalized the liquidation of our Russian operations, and the cost of that. The final cost of that liquidation, €3.3 million, is included here in other expenses, and fixed costs of €50 million are according to our plan. As we widen and progress our research and development pipeline, we continue to accelerate our sales. Part of this increase in sales and marketing costs is due to higher royalties paid to Bayer, as Nubeqa sales continue to perform well. And now, I will move to the first half of this year, from January to June. We see very similar figures here. Growth increased by 22%, totaling €939 million in net sales during the first six months, with almost 60% growth in operating profit, up to €291 million, an operating profit margin of 31%, and earnings per share of €1.64. Innovative medicines are clearly the driver for the growth. Here we can see Q2 numbers on the left and then the first half in the middle. It is really more than 60% growth both in the second quarter and during the first six months. Royalties are playing the biggest role, followed by a smaller share of other services to our partners. And I think the most important message here is on the right-side figure with the columns on different quarters, where we can once again underline the dynamics of the Nubeqa royalty income growth for Orion. It is very back-end loaded during one financial year. If you look here at Q1 2026 and compare it to the previous quarter. Q2 saw a significant increase in royalties, but also in tablet deliveries to Bayer. I think we also previously stated that the tablet deliveries may vary between the quarters. And this time there were a lot of deliveries from Orion to Bayer. Branded products. Q2 was strong, as I mentioned, almost 13% growth compared to the previous year's Q2. The biggest percentage increase was in women's health with our Divina product range, mainly Divigel, which is an estradiol gel for hormone replacement therapy. Easyhaler franchise grew 7% and Arthro. The combination product, Budesonide Formoterol, contributed mainly to that growth, while CNS was actually decreasing. Net sales decreased slightly due to price changes or price decreases in some of our global markets. Generics and consumer health were on par compared to the previous year's second quarter and also to the previous first half. First half of the previous year. The decline, a very slight decline here, comes from the generic prescription drugs, as the consumer health products are actually growing with a healthy percentage. I cannot resist saying here that if we were to exclude Simdax and Dexdor from this portfolio and look purely at our generic portfolio, not including legacy products. The generic business growth was 2%, a very healthy growth percentage for a generic business in Europe. We also entered into a license agreement for European rights to a new Nivolumab biosimilar with Shilpa, a partner with whom we are already developing products, and we are expecting to launch this new biosimilar in the 2030s. Animal Health had a tougher quarter in Q2, but let us remember that the previous year's Q2 was, if not an all-time high, exceptionally high. So the comparison period was tough. And it's always a question of deliveries to our partners in this business. And when you look at the first half of this year compared to the previous one, it is down 2.4%. And we are expecting the growth to accelerate towards the latter part of the year. We also received very good news, an approval by the FDA for a new product called Tessie. The molecule is Tasipimidine. It is an oral solution for anxiety and fear in dogs, especially if they go to strange places or need to experience new conditions. And we expect our partner to start commercial sales in mid-2027. And Fermion. External sales saw almost 20% growth in Q2 and 17% during the first half of the year. Here, the delivery timing is everything. So these are big quantities that we sell to our business-to-business customers. So we can clearly see that the first half of this year has been very busy on that front. I am sharing this since there has been news in Finnish by the Finnish Broadcasting Company that there was water damage at one of the Fermion plants in Hanko last week during the summer maintenance period. We are fully recovering from that water damage. All the activities are being implemented as we speak. Based on our current understanding, this will not have a material effect or impact on Orion, nor will it cause any disruption to the continuity of our key products. Our top ten product list tells the same story as the therapy areas or the divisions. I am not going to go through the products in detail, but I think the key message on this slide is clearly that now, already in Q2, Innovative Medicines is the biggest division in Orion, with Generics being the second biggest and Branded Products the third biggest division. Our clinical development pipeline has remained consistent with the previous Q1 report. No new projects have been included, and no new stages have been entered. We already reported last time that we had started the combination study with our inhibitor ODM-212. And now most of the readouts for these studies are actually in 2027 or 2028, like for Nubeqa studies and opevesostat studies. But we are expecting the LEV-10 study to be read out during the latter part of this year. I have already mentioned ODM-212. Let's look at it in more detail. Let's look at that molecule in a bit more detail. So ODM-212 is a TEAD inhibitor, and we develop it for certain cancers. It has two different mechanisms that we can use for the benefit of cancer patients. The first has to do with the Hippo pathway, and some cancers are driven by it. The tumor growth is driven by this Hippo pathway. So with this inhibitor, which binds to the TEAD transcription factors, we can actually limit the growth of the tumor in these certain cancers. And currently we are studying malignant pleural mesothelioma and epithelioid hemangioendothelioma. These are very rare cancers for which there is no specific treatment currently available. So if we can find a solution for patients, it would be really great. And based on our phase one results, we strongly believe so. The other part of the story for a TEAD inhibitor is that it can also prevent resistance. Resistance to some currently used cancer medication is prevented, because it also limits some of the mechanisms that cells can develop to circumvent treatment. For example, immune checkpoint inhibitors, chemotherapy, or KRAS inhibitors. And here we talk about different cancer types like pancreatic cancer, non-small cell lung cancer (NSCLC), and also mesothelioma. So there are two ways to use this TEAD inhibitor: specifically for a certain cancer that is driven by this Hippo pathway, or to prevent resistance to currently used cancer medication. So far, we have carried out a phase one study as a monotherapy using only ODM-212, and we have seen very promising results on the efficacy. Of course, those are very early signals in mesothelioma and EHE. And we have also seen a very good side effect profile. We know that in oncology, sometimes even a bit rougher side effect profile is accepted. But here we really can see that it's very well tolerated. And based on these results, which we actually announced at ASCO this year, we started a phase two study for mesothelioma and EHE. This study is currently ongoing and expected to read out in late 2027. Based on this monotherapy study with ODM-212, we also initiated a combination study with some of the usually used drugs, such as the ones that I already mentioned for pancreatic cancer, non-small cell lung cancer, and mesothelioma. And as we think that we have a potentially best-in-class TEAD inhibitor in our hands, we also believe that if this study is successful, we can solve many problems that are related to the resistance of current medication. And this could become a drug of choice to be combined with those medications. We also received orphan drug designation in the U.S. and Europe for mesothelioma and EHE. And that, of course, validates our belief that this is a very important study and an important drug for patients. We are currently eagerly awaiting the combination study results. The study is a Phase 1b/2 study. As we are also trying to find a suitable dosing for these combination studies before we go seamlessly into phase two. So these studies' readout is in 2029. Now to a very different topic: sustainability. Orion was listed, I think for the fifth or sixth time now, as one of Europe's Climate Leaders by the Financial Times this year. And I think this graph speaks for itself. As you can see, our emissions have decreased year by year. We started the program many years ago, and in 2019, we switched fully to clean, carbon-free electricity. And we have also carried out many different activities to reach our goal. We changed from crude oil in our steam production first to gas, then electricity. We have local heat stations on our campuses where we use the heat recovered from our manufacturing facilities for the whole campus. We are also carrying out many different types of renovations to be as carbon neutral as possible. We also understand that there is a way to go. And finally, I think the last piece of the emissions will be compensated in the end. And today we specified our outlook for this year. This is another strong quarter. So we thought that this is the place to do it. So we actually raised the lower range of our outlook by 50 million. So now the range for net sales is from 2 billion to 2.1 billion. And the range for our operating profit is from 650 million to 750 million. And here you can see our upcoming events. Next time we will be reporting in late October, and then the full-year report of 2026 will be in the middle of February. I thank you for your attention.
Thank you, Lisa, for the presentation. And now it's time to open up the floor for questions. As I mentioned in the beginning, we will start with the conference call lines. But please remember that you can also type in your questions by using the webcast chat function. But with this, I would like to hand over to the operator for the first questions, please.
If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Sean Homma from Jefferies. Please go ahead.
Hi. Thank you for taking my questions. Just two from me, please. Firstly, could you provide some color as to the significant increase in Nubeqa sales? Is it a good proxy for the remainder of the year? And then secondly, are you able to disclose? At which point during the quarter did you reach the highest royalty tier, and what is the rate, or at least the range of the rate? Thank you so much.
Thank you very much. I will start, and I will let Rene continue. On the royalty rate. So your question was on the tablet deliveries. And there is nothing secretive or strange there. It is really as we have stated; we deliver tablets according to Bayer's forecasts. Sometimes the deliveries and manufacturing campaigns are timed in our manufacturing so that there is a larger volume of tablets sent out during one quarter. But if there is a one-day delay, the deliveries and higher numbers are seen in the following quarter. So, of course, the trend overall will be growing, and the tablet deliveries will be growing, but there will still be some variation between the quarters. So I think that is not a very good key indicator for the future growth to look at it from one quarter to another. If you want to estimate the growth of Nubeqa in the marketplace, maybe, Rene, you want to say something about the royalty rate.
Yeah. And to continue regarding tablet sales, of course, we always have the maintenance break in our factories during the summertime. And of course, before that, we try to also build in a little bit more of shipments. And those went out now nicely at the end of the quarter. So you saw this big jump in tablet sales. But as Liisa said, it is not necessarily always going as a very continuous step, but there can be step changes in either direction depending on how the big shipments go out and then on the royalties. Unfortunately, we cannot disclose any further information regarding the timing. We said that it was reached during Q2. The maximum tier. We haven't disclosed what the maximum percentage is, but I'm sure you will be able to arrive at a reasonable range when you compare the numbers.
Thanks so much.
The next question comes from Iris le Man from DNB Carnegie. Please go ahead.
Hello, this is from DNB Carnegie. I have several questions and I will take them one by one. So basically, the first one is, what was the reason behind your guidance upgrade? And was it driven mainly by your Q2 performance, or have you also upgraded your estimates for H2?
Yes, thanks for the question. Of course, when we look at the first half of the year, we are having good momentum, especially with Nubeqa. We think that momentum will continue in the H2, and for that reason, we of course look at the whole full-year situation. And that led us to upgrade the lower boundary of the range higher. As we saw that lower boundary, the probability to land in there started to be very low in our scenarios.
Exactly.
Okay. And then secondly, sales of Divina increased a lot; were there any difficulties with peer supply that increased demand?
Thank you for the question. If I heard correctly, you are asking about the other company's supply. Did I get that right? Yes. Well, exactly. Thanks. Yes, we have seen and heard that there are actually some products and patches experiencing a stock out in the Nordic countries. And what we have seen actually during this year and even last year is on average 40% growth of the Divina product portfolio, maybe even above 40%. You could speculate that the additional maybe slightly under 10% could be a result of stock outs of some other hormone replacement therapies, because patients really have to go to see a doctor to get a new prescription for another product. So you cannot really do the change at the pharmacy. So it really needs to go via a doctor. But clearly, it is a treatment that needs to be continued. So I could imagine that we see some of our growth, also some of that stock-out is reflected in our growth.
Okay. And is that going to be still an issue in Q3?
Well, that is a very difficult question. I don't really know about the other company's production capabilities, but as I said, we've seen a constant growth of around 40% for Divina, even without these competitor stockouts. So I would estimate that the growth will continue even in the second half of this year, at that rate, at least.
Good. And thirdly, what is your current plan for ODM-212? Do you plan to develop it yourself, or are you looking for a partner before the phase three study?
A very good question. Currently, we are not looking for a partner. We are running our studies. We are running the phase two study by ourselves, and our plan is to run the phase three study also by ourselves, especially for the monotherapy, but also hopefully for the combination therapy. So there are no plans currently to look for a partner.
And my final question is regarding tariffs. So what are your current expectations for this year regarding the impact from tariffs and what is your outlook for next year.
Well, I think, Rene. Good.
Yeah. The latest is that we assume that there will be tariffs for innovative pharma from Europe in the last quarter of this year, starting from the beginning of October. We have also included some impact for that in our forecast. Not a big one for this year, but of course next year with four full quarters. If that impact comes, then of course, it is a larger one. And in the end, we have to see how that is impacting us. But of course there is also some uncertainty. We have to see how it's calculated in the end. So I think that's also something which hasn't been tested. But so far, the impact this year is small, and next year it will be a bit bigger. And hopefully it will not be a significant one. But we'll have to see how it develops.
Okay. Thank you.
The next question comes from Sami Sarkama from Danske Bank Markets. Please go ahead.
Hi. I have a couple of questions. We will also be taking these one by one, starting from Nubeqa. Firstly, you said that deliveries were on the high side in the second quarter. Are you suggesting that we will see lower deliveries in the third and fourth quarters relative to the second quarter level?
Well, I think that's a fair assumption in every year that in Q3 we do have the maintenance break. So there is at least one month. The maintenance break is usually 4 to 6 weeks. So there is less manufacturing during the Q3. So that is usually fewer deliveries as well. But then again, in Q2. Q4, we are usually fully geared up. So then you might see this fluctuation again between the quarters.
Okay. And then I'm wondering, did you make any accounting catch-ups related to Nubeqa sales that you estimated in the first quarter of the year?
There are always some corrections that we do on a monthly basis, but we are not disclosing how much we correct on a monthly basis.
Exactly.
But typically these are not very big. So we have a pretty good understanding and estimates on a monthly basis.
Okay. So, probably nothing material in the second quarter. But maybe on the positive side.
Well, I have nothing to comment on that side.
Okay. Then, I was wondering about the Fermion incident in Hanko. You are not estimating any material financial impacts, but just curious, could we see changes to, let's say, normal seasonality, for example, that you would not be able to deliver full volumes in the third quarter yet. Could this have any timing impacts? If we think about the rest of the year, do you see any risk of additional costs? And when do you expect to restore the production volumes in full?
Well, as we stated, we don't currently see any material effect of this damage to Orion or the supply of the product for the patients. Of course, it will take some time to get it prepared again to full force. But as it is the maintenance break, it goes as part of that maintenance work now to get it fixed.
Okay. So I guess you are talking about weeks and not months.
Yes, rather weeks than months.
Okay. And then one final question regarding Fermion. We have seen quite good growth this year; in the past, you may not have been able to grow the business because you were using most of the capacity yourself. So what, in a way, explains that you are able to service also other customers now when Nubeqa is growing heavily. And what is the outlook for the second half of the year on this front?
Well, let me start from a bit further. Of course, Fermion first of all has two sites, both Oulu and Hanko. And on both sides in Hanko, we have four plants. And in all, we have nine modules. So we actually manufacture APIs in many different plants, so to speak. If we calculate modules also as plants, then Darolutamide does not have an effect on all of them. So the fact that we've been able to deliver external products is that there might be, I don't know exactly the product mix, but there might be big deliveries from our Olo factory as well to our CMO customers or from our other plants in Hanko than the plants that are also manufacturing Darolutamide.
Okay. And are you expecting to maintain this good level also during the second half of the year?
No, I think it will be leveling out during the rest of the year.
Okay. Thanks. I have no further questions.
The next question comes from Alex Moore from Bank of America. Please go ahead.
Hi. Yeah. I thought I could just ask a follow-up on the Nubeqa royalties question. So the royalty growth looks super strong in the quarter. And as you have stated, you reached the highest royalty level in Q2. Q2. So how should we therefore think about sequential quarter-on-quarter growth in royalties for Q3 and Q4? Should we expect this to moderate a bit closer to underlying in-market sales growth for Nubeqa? And then looking ahead, do you expect to see continued fast progression or faster progression through royalty tiers in 2027 compared to 2026?
Maybe I can take that one. So naturally, if you reach the maximum royalty tier already, it means that the rest of the quarters of the year will be more driven by the market sales and not by reaching any new tiers. So that is of course something which happens. And for next year, of course, we will have to see when we guide that. But of course, we see overall in the big picture of Nubeqa that there is still a lot of growth left there. So, of course, we assume that there will be year-on-year growth for many years to come.
Maybe if I can add on to that, last year we reached the ceiling in terms of the royalty rate during Q3. So still in Q3 we will be enjoying the fact that we are now benefiting from the highest royalty rate for the full quarter compared to last year. And on top of that, of course, the market sales increase.
Okay. Could I ask a follow-up on R&D?
Sure. Please go.
Ahead. Please.
That is fine. So just on R&D cadence, you've previously indicated that you expect R&D costs to increase for the full year compared to last year. And we saw quite a big, meaningful 29% increase in Q2 this year versus Q1. Should we view the level of quarter-on-quarter growth in R&D spend as a reasonable run rate for the second half, or do you expect sequential R&D growth to flatten somewhat in Q3 and Q4?
It is a good question. And of course, the year-on-year growth in Q2 was quite significant, as you mentioned. And I would be careful of using that as a full-year measure. So I think what we said at the beginning of the year was that this year's R&D costs are going to increase because we have more projects. It will be more like a continuous change, not a big quantum leap this year. I think you have to look at full-year comparisons, as a single quarter can have a lot of fluctuations. And this year's Q1 may have started out a bit slow. And then this Q2, we stepped up in terms of the project in ODM-212. So now we have perhaps reached a different run rate than we had in Q1. But I think it is careful not to assume that you would have a similar type of growth each quarter.
Thanks. I do not have any further questions.
The next question comes from Matti Korolev from OP Corporate Bank. Please go ahead.
Hi. Good afternoon.
On my behalf as well. I'd like to address the very strong gross margin that you had during this quarter. So of course, I think there is a sales mix impact from the increasing Nubeqa sales. And the share of the branded products is driving the whole group-wide gross margin up. But still, it is a very strong growth. Are there any changes in your underlying business? If we think about Generics or any other segment that is boosting the profitability?
I think the main driver you already mentioned is really that as Nubeqa royalties take a bigger share and grow so fast, that of course impacts the gross margin. That is absolutely the primary factor. The other businesses' gross margins are more stable from that perspective.
Okay, then maybe one more question regarding Nubeqa, but perhaps from a longer-term view. Next year, you mentioned that you might have a significant headwind from tariffs, but what are you expecting regarding the growth rate of Nubeqa market sales? And there is one competing product losing its exclusivity. So are you expecting that to result in taking over some market share or exerting pricing pressure?
Well, yes, indeed. We are aware of this. And as Bayer makes the market forecast, it is better to ask Bayer this question, but to our knowledge, based on discussions with Bayer, this has been absorbed in all the forecasts. The effect of the study becoming generic. We are expecting strong growth going forward into next year and the years after that.
Okay. No further questions.
The next question comes from Anssi Rossi from SEB. Please go ahead.
Yes. Hi all. It's from SEB.
Thank you for the presentation. And I have only one question left regarding Nubeqa and the study. So could you maybe remind us about the timing of this study? So is it early 2027 when they should be completed? And then how should we think about your R&D expenses? So I guess this study is requiring some expenses from that side.
Thanks, Steve. Yeah. Now we cannot recall exactly what the timing is within 2027. So it is 2027. But we can come back to that later on if needed. And that is public information on clinicaltrials.gov. So we are basing our assumptions on that information. Unfortunately, I cannot remember the exact month or quarter.
And then there was a question.
About what that was.
Yeah.
Yeah. So of course, there we are. We are most likely participating as well in this Phase III trial. So there will be incremental costs in R&D as well. But overall, this remains part of our R&D budget at that point in time. From that perspective, it is nothing major. From that perspective. So it is again an incremental part of the budget.
Okay. Thanks.
There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.
Thank you. Operator. Now we are turning to the webcast questions. We have actually one follow-up here from Iris from DNB, Carnegie. So can you provide an update on your US expansion? What have you done so far? And are you planning to accelerate your presence, for example, by hiring more people? I just wanted to understand how we should think about your US expansion and cost development this and next year?
Yes. Thank you for that question. Next question. Indeed. We are expanding our team in the US in Boston. We have a strong team in clinical, regulatory, biostatistics, and in R&D. That is how we started out. And now we also have a commercial head in the US; we are hiring and extending the commercial group with medical affairs and market access. But these are single individuals. So we are not talking about any kind of significant change in the level of costs at this time. So this is all preparing for ODM-212 phase planning of phase three studies and preparing the ground with the hospitals and key opinion leaders. So it's still single individuals. Regarding the cost hike. If that comes, then it comes very close to the launch. When you start to recruit the sales reps for the launch. So, of course, our cost base in the U.S. is very different than it used to be even last year, not to mention in 2022 when we did not have the U.S. operation. But it is still nothing material or in any way significant. So it is tens of people, not hundreds of people.
All right. Thank you, Lisa. We seem to have no further questions on the webcast. So at this point, thank you all for attending this webcast. So next time, as Lisa said, we will be reporting in late October. So meanwhile, we want to wish you all a great summer.
Thank you, thank you.



















